These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35152272)

  • 1. Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.
    Kim JS; Taaffe DR; Galvão DA; Hart NH; Gray E; Ryan CJ; Kenfield SA; Saad F; Newton RU
    Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):86-92. PubMed ID: 35152272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT.
    Kim JS; Wilson RL; Taaffe DR; Galvão DA; Gray E; Newton RU
    Med Sci Sports Exerc; 2022 Feb; 54(2):197-205. PubMed ID: 34559721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer.
    Kim JS; Taaffe DR; Galvão DA; Clay TD; Redfern AD; Hart NH; Gray ES; Ryan CJ; Kenfield SA; Saad F; Newton RU
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):795-801. PubMed ID: 36446945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.
    Newton RU; Kenfield SA; Hart NH; Chan JM; Courneya KS; Catto J; Finn SP; Greenwood R; Hughes DC; Mucci L; Plymate SR; Praet SFE; Guinan EM; Van Blarigan EL; Casey O; Buzza M; Gledhill S; Zhang L; Galvão DA; Ryan CJ; Saad F
    BMJ Open; 2018 May; 8(5):e022899. PubMed ID: 29764892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise Improves V˙O2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients.
    Wall BA; GALVãO DA; Fatehee N; Taaffe DR; Spry N; Joseph D; Hebert JJ; Newton RU
    Med Sci Sports Exerc; 2017 Aug; 49(8):1503-1510. PubMed ID: 28319589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
    Kenfield SA; Van Blarigan EL; Panchal N; Bang A; Zhang L; Graff RE; Chen YH; Ryan CJ; Luke A; Newton RU; Tenggara I; Schultz B; Wang E; Lavaki E; Zuniga K; Pinto N; Borno H; Aggarwal R; Friedlander T; Koshkin VS; Harzstark A; Small E; Chan JM
    Cancer Med; 2021 Nov; 10(22):8058-8070. PubMed ID: 34636156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.
    Hart NH; Newton RU; Spry NA; Taaffe DR; Chambers SK; Feeney KT; Joseph DJ; Redfern AD; Ferguson T; Galvão DA
    BMJ Open; 2017 May; 7(5):e014458. PubMed ID: 28559456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.
    Sheill G; Brady L; Guinan E; Hayes B; Casey O; Greene J; Vlajnic T; Cahill F; Van Hemelrijck M; Peat N; Rudman S; Hussey J; Cunningham M; Grogan L; Lynch T; Manecksha RP; McCaffrey J; Mucci L; Sheils O; O'Leary J; O'Donnell DM; McDermott R; Finn S
    Trials; 2017 Oct; 18(1):456. PubMed ID: 28978344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise-induced myokines and their effect on prostate cancer.
    Kim JS; Galvão DA; Newton RU; Gray E; Taaffe DR
    Nat Rev Urol; 2021 Sep; 18(9):519-542. PubMed ID: 34158658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer.
    Hanson ED; Stopforth CK; Alzer M; Carver J; Lucas AR; Whang YE; Milowsky MI; Bartlett DB; Harrison MR; Hayes A; Bitting RL; Deal AM; Hackney AC; Battaglini CL
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):725-732. PubMed ID: 33495569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases.
    Galvão DA; Taaffe DR; Spry N; Cormie P; Joseph D; Chambers SK; Chee R; Peddle-McIntyre CJ; Hart NH; Baumann FT; Denham J; Baker M; Newton RU
    Med Sci Sports Exerc; 2018 Mar; 50(3):393-399. PubMed ID: 29036016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
    Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
    Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States).
    Ngo TH; Barnard RJ; Tymchuk CN; Cohen P; Aronson WJ
    Cancer Causes Control; 2002 Dec; 13(10):929-35. PubMed ID: 12588089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases.
    Cormie P; Newton RU; Spry N; Joseph D; Taaffe DR; Galvão DA
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):328-35. PubMed ID: 23917308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.
    Sharma J; Gray KP; Evan C; Nakabayashi M; Fichorova R; Rider J; Mucci L; Kantoff PW; Sweeney CJ
    Prostate; 2014 Feb; 74(3):225-34. PubMed ID: 24132762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.
    Bultijnck R; Deforche B; Borrey N; Van Bauwel J; Lievens M; Rammant E; Fonteyne V; Decaestecker K; Steyaert A; Lumen N; Ost P
    World J Urol; 2021 Feb; 39(2):357-364. PubMed ID: 32008114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.